Advanced search    

Search: authors:"Prajnan Das"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer

Background Over the last two decades, intraperitoneal chemotherapy has been found to have activity for select subgroups of patients with carcinomatosis from colon, ovarian, appendiceal, and recently, gastric origins. However, there is little data to support an aggressive surgical approach of cytoreduction (debulking) and hyperthermic intraperitoneal perfusion with chemotherapy...

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

Purpose To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation (CRT) in unresectable pancreatic cancer. Methods Seventeen patients with CT-staged, biopsy-proven unresectable pancreatic cancer were enrolled between 3/2008 and 10/2010. Prior chemotherapy was permitted. Two...

Reirradiation to the abdomen for gastrointestinal malignancies

Background Reirradiation to the abdomen could potentially play a role in palliation of symptoms or local control in patients with gastrointestinal malignancies. Our goal was to retrospectively determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal cancer patients treated with reirradiation to the abdomen. Methods Between November 2002...

ACR Appropriateness Criteria®  Resectable Rectal Cancer

Radiation Oncology ACR Appropriateness Criteria William E Jones III 8 Charles R Thomas Jr 0 Joseph M Herman 7 May Abdel-Wahab 13 Nilofer Azad 12 William Blackstock 11 Prajnan Das 10 Karyn A Goodman ... reported “Nucletron, Genentech” As of June 27, 2011, Prajnan Das, MD reported “Research Support – Genentech” For the remaining authors none were declared. Authors’ contribution WJ, CT, JM, MW, NA, WB, PD

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated

We retrospectively evaluated acute toxicity in 88 patients that were treated with capecitabine and concurrent radiotherapy to the upper abdomen. These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) with ampullary carcinoma, 11 (13%) with other primary tumors, 14 (16%) with liver metastases, and 6 (7%) with metastases at other...